Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | FABP4 | P15090 | 3/20 | 0.38 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18178774 | 0.91 | PTGDR2 (0.40) | PTGDR2FFAR4FFAR1NPC1MRGPRX4 | |
| SCHEMBL18182450 | 0.90 | TP53 (0.41) | PTGDR2TP53HTTFFAR4FFAR1 | |
| SCHEMBL18178300 | 0.89 | FABP4 (0.43) | PTGDR2TP53HTTFFAR4FFAR1 | |
| SCHEMBL18178674 | 0.88 | MRGPRX4 (0.39) | PTGDR2TP53HTTFFAR4FFAR1 | |
| SCHEMBL18178610 | 0.88 | ACLY (0.39) | PTGDR2FFAR4MRGPRX4MAPTLMNA | |
| SCHEMBL18530980 | 0.87 | PTGDR2 (0.49) | PTGDR2TP53HTTFFAR4FFAR1 | |
| SCHEMBL18178652 | 0.87 | PTGDR2 (0.46) | PTGDR2TP53HTTFFAR4FFAR1 | |
| SCHEMBL18178677 | 0.87 | MRGPRX4 (0.36) | HTTNPC1MRGPRX4MAPTLMNA | |
| SCHEMBL18178668 | 0.86 | MRGPRX4 (0.36) | PTGDR2TP53HTTFFAR4FFAR1 | |
| SCHEMBL18182896 | 0.86 | PTGDR2 (0.39) | PTGDR2FFAR4FFAR1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9573904-B2 | Aromatic compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-02-21 | — | — | US | disclosed |
| US-20160311775-A1 | AROMATIC COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311775-A1 | AROMATIC COMPOUND AND USE THEREOF | ZCCHC8, CBR3, CBX8 | PTGDR2 4455/4885TP53 4147/4885HTT 4153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.